FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018092044> ?p ?o ?g. }

• W2018092044 endingPage "2403" @default.
• W2018092044 startingPage "2396" @default.
• W2018092044 abstract "Purpose The MAGE-A3 protein is expressed in approximately 35% of patients with resectable non–small-cell lung cancer (NSCLC). Several immunization approaches against the MAGE-A3 antigen have shown few, but often long-lasting, clinical responses in patients with metastatic melanoma. Patients and Methods A double-blind, randomized, placebo-controlled phase II study was performed assessing clinical activity, immunologic response, and safety following immunization with recombinant MAGE-A3 protein combined with an immunostimulant (13 doses over 27 months) in completely resected MAGE-A3–positive stage IB to II NSCLC. The primary end point was disease-free interval (DFI). Results Patients were randomly assigned to either MAGE-A3 immunotherapeutic (n = 122) or placebo (n = 60). After a median postresection period of 44 months, recurrence was observed in 35% of patients in the MAGE-A3 arm and 43% in the placebo arm. No statistically significant improvement in DFI (hazard ratio [HR], 0.75, 95% CI, 0.46 to 1.23; two-sided P = .254), disease-free survival (DFS; HR, 0.76; 95% CI, 0.48 to 1.21; P = .248), or overall survival (HR, 0.81; 95% CI, 0.47 to 1.40; P = .454) was observed. Corresponding analysis after a median of 70 months of follow-up revealed a similar trend for DFI and DFS. All patients receiving the active treatment showed a humoral immune response to the MAGE-A3 antigen, although no correlation was observed with outcome. No significant toxicity was observed. Conclusion In this early development study with a limited number of patients, postoperative MAGE-A3 immunization proved to be feasible with minimal toxicity. These results are being investigated further in a large phase III study." @default.
• W2018092044 created "2016-06-24" @default.
• W2018092044 creator A5001374436 @default.
• W2018092044 creator A5004874011 @default.
• W2018092044 creator A5006704059 @default.
• W2018092044 creator A5020481714 @default.
• W2018092044 creator A5021704329 @default.
• W2018092044 creator A5034437880 @default.
• W2018092044 creator A5036470659 @default.
• W2018092044 creator A5037655196 @default.
• W2018092044 creator A5044950127 @default.
• W2018092044 creator A5052062735 @default.
• W2018092044 creator A5052564963 @default.
• W2018092044 creator A5053021947 @default.
• W2018092044 creator A5060795077 @default.
• W2018092044 creator A5067455713 @default.
• W2018092044 creator A5074397827 @default.
• W2018092044 creator A5075833287 @default.
• W2018092044 creator A5079950719 @default.
• W2018092044 creator A5084614193 @default.
• W2018092044 creator A5084931180 @default.
• W2018092044 date "2013-07-01" @default.
• W2018092044 modified "2023-10-15" @default.
• W2018092044 title "Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results" @default.
• W2018092044 cites W1517693128 @default.
• W2018092044 cites W1750596124 @default.
• W2018092044 cites W1907932102 @default.
• W2018092044 cites W1966936031 @default.
• W2018092044 cites W1984306031 @default.
• W2018092044 cites W1984655584 @default.
• W2018092044 cites W1990824056 @default.
• W2018092044 cites W1992699637 @default.
• W2018092044 cites W1993312546 @default.
• W2018092044 cites W2007669051 @default.
• W2018092044 cites W2019407271 @default.
• W2018092044 cites W2032975856 @default.
• W2018092044 cites W2048896826 @default.
• W2018092044 cites W2073252143 @default.
• W2018092044 cites W2087360336 @default.
• W2018092044 cites W2088720324 @default.
• W2018092044 cites W2094843657 @default.
• W2018092044 cites W2095065953 @default.
• W2018092044 cites W2104504726 @default.
• W2018092044 cites W2106787323 @default.
• W2018092044 cites W2117994949 @default.
• W2018092044 cites W2119282305 @default.
• W2018092044 cites W2127342594 @default.
• W2018092044 cites W2136236728 @default.
• W2018092044 cites W2158234609 @default.
• W2018092044 cites W2168278891 @default.
• W2018092044 cites W2463638162 @default.
• W2018092044 cites W4255758041 @default.
• W2018092044 doi "https://doi.org/10.1200/jco.2012.43.7103" @default.
• W2018092044 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23715567" @default.
• W2018092044 hasPublicationYear "2013" @default.
• W2018092044 type Work @default.
• W2018092044 sameAs 2018092044 @default.
• W2018092044 citedByCount "272" @default.
• W2018092044 countsByYear W20180920442013 @default.
• W2018092044 countsByYear W20180920442014 @default.
• W2018092044 countsByYear W20180920442015 @default.
• W2018092044 countsByYear W20180920442016 @default.
• W2018092044 countsByYear W20180920442017 @default.
• W2018092044 countsByYear W20180920442018 @default.
• W2018092044 countsByYear W20180920442019 @default.
• W2018092044 countsByYear W20180920442020 @default.
• W2018092044 countsByYear W20180920442021 @default.
• W2018092044 countsByYear W20180920442022 @default.
• W2018092044 countsByYear W20180920442023 @default.
• W2018092044 crossrefType "journal-article" @default.
• W2018092044 hasAuthorship W2018092044A5001374436 @default.
• W2018092044 hasAuthorship W2018092044A5004874011 @default.
• W2018092044 hasAuthorship W2018092044A5006704059 @default.
• W2018092044 hasAuthorship W2018092044A5020481714 @default.
• W2018092044 hasAuthorship W2018092044A5021704329 @default.
• W2018092044 hasAuthorship W2018092044A5034437880 @default.
• W2018092044 hasAuthorship W2018092044A5036470659 @default.
• W2018092044 hasAuthorship W2018092044A5037655196 @default.
• W2018092044 hasAuthorship W2018092044A5044950127 @default.
• W2018092044 hasAuthorship W2018092044A5052062735 @default.
• W2018092044 hasAuthorship W2018092044A5052564963 @default.
• W2018092044 hasAuthorship W2018092044A5053021947 @default.
• W2018092044 hasAuthorship W2018092044A5060795077 @default.
• W2018092044 hasAuthorship W2018092044A5067455713 @default.
• W2018092044 hasAuthorship W2018092044A5074397827 @default.
• W2018092044 hasAuthorship W2018092044A5075833287 @default.
• W2018092044 hasAuthorship W2018092044A5079950719 @default.
• W2018092044 hasAuthorship W2018092044A5084614193 @default.
• W2018092044 hasAuthorship W2018092044A5084931180 @default.
• W2018092044 hasConcept C121608353 @default.
• W2018092044 hasConcept C126322002 @default.
• W2018092044 hasConcept C141071460 @default.
• W2018092044 hasConcept C142724271 @default.
• W2018092044 hasConcept C143998085 @default.
• W2018092044 hasConcept C147483822 @default.
• W2018092044 hasConcept C168563851 @default.
• W2018092044 hasConcept C203014093 @default.
• W2018092044 hasConcept C203092338 @default.

• next